



Please type a plus sign (+) inside this box → ☒

PTO/SB/21 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

1

Application Number

10/091,744

Filing Date

March 5, 2002

First Named Inventor

Holman, Andrew

Group Art Unit

1614

Examiner Name

Unassigned

Attorney Docket Number

020862-000110US

ENCLOSURES (check all that apply)

☐ Fee Transmittal Form

☐ Fee Attached

☐ Amendment / Response

☐ After Final

☐ Affidavits/declaration(s)

☐ Extension of Time Request

☐ Express Abandonment Request

☒ Information Disclosure Statement

☐ Certified Copy of Priority Document(s)

☐ Response to Missing Parts/
Incomplete Application

☐ Response to Missing
Parts under 37 CFR
1.52 or 1.53

☐ Assignment Papers
(for an Application)

☐ Drawing(s)

☐ Licensing-related Papers

☐ Petition Routing Slip (PTO/SB/69)
and Accompanying Petition

☐ Petition to Convert to a
Provisional Application

☐ Power of Attorney, Revocation
Change of Correspondence Address

☐ Terminal Disclaimer

☐ Request for Refund

☐ CD, Number of CD(s)

☐ After Allowance Communication to
Group

☐ Appeal Communication to Board of
Appeals and Interferences

☐ Appeal Communication to Group
(Appeal Notice, Brief, Reply Brief)

☐ Proprietary Information

☐ Status Letter

☒ Other Enclosure(s)
(please identify below):

Form PTO-1449; References AA-DY;
Return Postcard

Remarks

The Commissioner is authorized to charge any additional fees to
Deposit Account 20-1430.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm
and
Individual name

Townsend and Townsend and Crew LLP

Mark G. Sandbaken, Ph.D.

Reg. No. 39,354

Signature

Date

August 9, 2002

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date:

August 9, 2002

Typed or printed name

Jennifer M. Smolen

Signature

Date

August 9, 2002

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
SE 5013775 v1

1614
RECEIVED
AUG 14 2002
P.O. BOX 1600/2900

U.S. PATENT & TRADEMARK OFFICE
AUG 12 2002

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Asst. Commissioner of Patents and Trademarks, Washington, D.C. on Aug. 9, 2002
[Signature]

RECEIVED
TECH CENT
AUG 12 2002
PATENT & TRADEMARK OFFICE

Attorney Docket No. 020862-0001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of:

ANDREW HOLMAN
Application No.: 10/091,744
Filed: March 5, 2002
For: ADMINISTRATION OF SLEEP
RESTORATIVE AGENTS

Examiner: Unassigned
Art Unit: 1614

**INFORMATION DISCLOSURE
STATEMENT**

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Applicants direct the Examiner's attention to the references below, also listed on the accompanying Form PTO-1449. A copy of each is also enclosed.

The following U.S. Patents are set forth below by issue date:

- AA. U.S. Patent No. 4,452,808, issued June 5, 1984 to Gallagher, Jr.
- AB. U.S. Patent No. 4,843,086, issued June 27, 1989 to Griss, deceased *et al.*
- AC. U.S. Patent No. 4,886,812, issued Dec. 12, 1989 to Griss, deceased *et al.*
- AD. U.S. Patent No. 5,112,842, issued May 12, 1992 to Zierenberg *et al.*
- AE. U.S. Patent No. 5,650,420, issued Jul. 22, 1997 to Hall *et al.*
- AF. U.S. Patent No. 5,658,955, issued Aug. 19, 1997 to Hitzig.
- AG. U.S. Patent No. 5,694,950 issued Dec. 9, 1997 to McMichael.
- AH. U.S. Patent No. 5,696,128, issued Dec. 9, 1997 to Cincotta *et al.*
- AI. U.S. Patent No. 5,786,344 issued July 28, 1998 to Ratain *et al.*
- AJ. U.S. Patent No. 5,842,997, issued Dec. 1, 1998 to Verrier *et al.*

- AK. U.S. Patent No. 5,843,943 issued Dec. 1, 1998 to Carson *et al.*
- AL. U.S. Patent No. 5,872,127, issued Feb. 16, 1999 to Cincotta *et al.*
- AM. U.S. Patent No. 5,872,133, issued Feb. 16, 1999 to Cincotta *et al.*
- AN. U.S. Patent No. 5,905,083, issued May 18, 1999 to Cincotta *et al.*
- AO. U.S. Patent No. 5,921,940, issued Jul. 13, 1999 to Verrier *et al.*
- AP. U.S. Patent No. 5,932,252, issued Aug. 3, 1999 to Morris Jr. *et al.*
- AQ. U.S. Patent No. 5,952,389, issued Sept. 14, 1999 to Fogel.
- AR. U.S. Patent No. 6,001,861, issued Dec. 14, 1999 Oertel *et al.*
- AS. U.S. Patent No. 6,057,373, issued May 2, 2000 to Fogel.
- AT. U.S. Patent No. 6,156,777, issued Dec. 5, 2000 to Hall *et al.*
- AU. U.S. Patent No. 6,191,153, issued Feb. 20, 2001 to Hammer *et al.*
- AV. U.S. Patent No. 6,194,445, issued Feb. 27, 2001 to Oertel *et al.*
- AW. U.S. Patent No. 6,204,245 issued Mar. 20, 2001 to Siegel *et al.*
- AX. U.S. Patent No. 6,255,329, issued July 3, 2001 to Maj.
- AY. U.S. Patent No. 6,258,827, issued July 10, 2001 to Chenard *et al.*
- AZ. U.S. Patent No. 6,277,875, issued Aug. 21, 2001 to Holman.
- BA. U.S. Patent No. 6,294,583, issued Sept. 25, 2001 to Fogel.
- BB. U.S. Patent No. 6,300,365, issued Oct. 9, 2001 to Holman.

The following articles are set forth in alphabetical order:

BC. Aksoyek *et al.*, "Assessment of autonomic nervous system function in patients with Behcet's disease by spectral analysis of heart rate variability," *J. Auton. Nerv. Syst.* 77(2-3):190-4 (Sept. 24, 1999).

BD. Alvarez-Nemegyei *et al.*, "Bromocriptine in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled study," *Lupus* 7(6):414-9 (1998).

BE. Bathon, "Rheumatoid Arthritis-treatment," Abstract from the Highlights of the 1998 American College of Rheumatology National Scientific Meetings.

BF. Breedveld, "New tumor necrosis factor-alpha biologic therapies for rheumatoid arthritis," *Eur. Cytokine Netw.* 9:233-38 (1998).

BG. British Society for Rheumatology, The Programme from the XIXth Annual General Meeting , Brighton, UK (Apr. 23-26, 2002).

BH. Chokroverty and Jankovic, "Restless legs syndrome: A disease in search of identity," *Neurology* 52(5):907-10 (Mar 23, 1999).

BI. Damase-Michel *et al.*, "Effects of dopaminergic drugs on the sympathoadrenal system," *Hypertens Res.* 18(1):S119-24 (1995).

BJ. Drewes, "Pain and sleep disturbances with special reference to fibromyalgia and rheumatoid arthritis," *Rheumatology* (Oxford) 38(11):1035-1038 (Nov. 1999).

BK. Eijsbouts *et al.*, "Treatment of rheumatoid arthritis with the dopamine agonist quinagolide," *J. Rheumatol.* 26(10): 2284-5 (Oct. 1999).

BL. Elenkov *et al.*, "The Sympathetic Nerve - An Integrative Interface between Two Supersystems: The Brain and the Immune System," *Pharmacological Review* 52(4):595-638 (2000).

BM. Gao *et al.*, "Effects of dopaminergic agents on carrageenan hyperalgesia in rats," *Eur. J. Pharmacol.* 406(1): 53-8 (2000).

BN. Hanna *et al.*, "Switching from pergolide to pramipexole in patients with Parkinson's disease," *J. Neural. Transm.* 108:63-70 (2001).

BO. Hennig, "Restless Leg Syndrome: Diagnosis and Treatment," *Hospital Medicine*, pp. 54-75 (Nov. 1997).

BP. Holman, "Pramipexole for Fibromyalgia: Initial Observations and Rationale," Abstract: FAME meeting, Chicago, IL (Jun. 22-23, 2001).

BQ. Holman, "The Relationship of Sleep and Autonomic Function on Autoimmune Disease," Abstract: FAME meeting, Chicago, IL (Jun. 22-23, 2001).

BR. Holman, "Safety and Efficacy of the Dopamine Agonist, Pramipexole, on Pain Score for Refractory Fibromyalgia," Arthritis and Rheumatism, Abstract for: 2000 Annual Scientific Meeting 43:9 1599 (2000).

BS. Honda *et al.*, "Dopamine D₃ agonists into the substratia nigra aggravates cataplexy but do not modify sleep," *NeuroReport* 10(14): 3111-8 (Sept. 1999).

BT. Huynh *et al.*, "The Effects of Pramipexole in a Rodent Model of Early Parkinson's Disease," Online Abstract, Short Term Training Program, Department of Neurology, School of Medicine, UCLA, Los Angeles, CA (Summer 2001).

BU. Lagos *et al.*, "Effects of the D₃ preferring dopamine agonist pramipexole on sleep and waking, locomotor activity and striatal dopamine release in rats," *Eur. Neuropsychopharmacol.* 8(2):113-20 (May 1998).

BV. Lam, "Clinical pharmacology of dopamine agonists," *Pharmacotherapy* 20(1 Pt. 2): 17S-25S (2000).

BW. Leanos Miranda *et al.*, "Prolactin as an immunomodulator," *Rev. Alerg. Mex.* 44(5):116-23 (Sept-Oct., 1997).

BX. Lechin *et al.*, "Plasma neurotransmitters and cortisol in chronic illness: role of stress," *J. Med.* 25(3-4): 181-92 (1994).

BY. Lieberman, "Management of Patients With Newly Diagnosed PD," Published in *Young Parkinson's Handbook*, Chapter 3: The Medical Management of PD, <http://spauldingrehab.mgh.harvard.edu> (printed Nov. 19, 2001).

BZ. Lin *et al.*, "Effect of pramipexole in treatment of resistant restless legs syndrome," *Mayo Clin. Proc.* 73(6):497-500 (Jun. 1998).

CA. Lorenc-Koci and Wolfarth, "Efficacy of pramipexole, a new dopamine receptor agonist, to relieve the Parkinsonian-like muscle rigidity in rats," *Eur. J. Pharmacol.* 385(1):39-46 (1999).

CB. Luchsinger *et al.*, "Comparative effects of dopaminergic agonists on cardiovascular, renal, and renin-angiotensin systems in hypertensive patients," *J. Clin. Pharmacol.* 32(1):55-60 (1992).

CC. Mader, "Bromocriptine for refractory rheumatoid arthritis," *Harefuah* 133(11):527-9, 591 (Dec. 1, 1997).

CD. Maj *et al.*, "Antidepressant effects of pramipexole, a novel dopamine receptor agonist," *J. Neural. Transm.* 104: 4-5, 525-33 (1997).

CE. Maj *et al.*, "The effect of repeated treatment with pramipexole on the central dopamine D₃ system," *J. Neural. Transm.* 107(12): 1369-79 (2000).

CF. Mannelli *et al.*, "In Vivo Evidence That Endogenous Dopamine Modulates Sympathetic Activity in Man," *Hypertension* 34:398-402 (1999).

CG. Mannelli *et al.*, "Dopamine and sympathoadrenal activity in man," *Clin. Exp. Hypertens.* 19(1-2):163-79 (1997).

CH. Martinez-Lavin *et al.*, "Circadian studies of autonomic nervous balance in patients with fibromyalgia," *Arthritis & Rheumatism* 41:1966-71 (Nov. 1998).

CI. Mehta *et al.*, "Heart rate variability in healthy newborn infants," *Am. J. Cardiol.* 89(1):50-3 (Jan. 1, 2002).

CJ. Mohler, "Pramipexole in the treatment of advanced Parkinson's disease," *Eur. J Neurology Suppl.* (Suppl. 1):21-25 (2000).

CK. Mohler *et al.*, "Soluble Tumor Necrosis Factor (TNF) Receptors Are Effective Therapeutic Agents in Lethal Endotoxemia and Function Simultaneously as Both TNF Carriers and TNF Antagonists," *J. Immunol.* 151:1548-1561 (Aug. 1, 1993).

CL. Monti and Monti, "Role of dorsal raphe nucleus serotonin 5-HT_{1A} receptor in the regulation of REM sleep," *Life Sci.* 66(21):1999-2012 (2000).

CM. Montplaisir *et al.*, "Restless legs syndrome improved by pramipexole: a double-blind randomized trial," *Neurology* 52(5):938-43 (1999).

CN. Montplaisir *et al.*, "Pramipexole in the treatment of restless legs syndrome: a follow-up study," *Eur. J. Neurol.* 7 Suppl. 1:27-31 (May 2000).

CO. Orr *et al.*, "Autonomic regulation of cardiac function during sleep in patients with irritable bowel syndrome," *Am. J. Gastroenterol.* 95(10): 2865-71 (2000).

CP. Penzel *et al.*, "Heart rate variability during sleep stages in normals and in patients with sleep apnea," *Stud. Health Technol. Inform.* 77:1256-60 (2000).

CQ. Prescott (ed.), "Lipid Vesicles as Carriers for Introducing Biologically Active Materials into Cells," *Methods in Cell Biology*, Volume XIV, Ch. 4, Academic Press, New York, N.Y. (1976).

CR. Quinn *et al.*, "Painful Parkinson's Disease," *Lancet* 1(8494):1366-9 (Jun. 14, 1986).

CS. Renzetti and Gater, "Ro 45-2081, a TNF receptor fusion protein, prevents inflammatory responses in the airways," *Inflamm. Res.* 46(2):S143-S144 (1997).

CT. Schilling *et al.*, Neuroendocrine and side effect profile of pramipexole, a new dopamine receptor agonist, in humans," *Clin. Pharmacol. Ther.* 51(5):541-8 (May 1992).

CU. Sears, "The evolution of β 2-agonists," *Respir. Med.* 95(B): S2-6 (Aug. 2001).

CV. Silber, "Concise review for Primary-Care Physicians: Restless legs syndrome," *Mayo Clin. Proc.* 72(3):261-4 (Mar. 1997).

CW. Sinoway, "Direct Assessment of Sympathetic Neural Activity in Patients with Heart Failure During Exercise," Abstract from Research Workshop entitled "Effect of Acupuncture on Cardiovascular Disease, Its Mechanism and Clinical Application", University of California at Irvine (Oct. 14-15, 2000).

CX. Sjolín and Trykker, "Unsuccessful treatment of severe pain from bone metastasis with Sinemet 25/100," *N. Engl. J. Med.* 312(10):650-1 (Mar. 7, 1985).

CY. Sun *et al.*, "Iron and the restless legs syndrome," *Sleep* 21(4):371-7 (1998).

CZ. Trenkwalder *et al.*, "Periodic limb movements and restless legs syndrome," *Neurol. Clin.* 14(3):629-50 (Aug. 1996).

DA. Tsuru *et al.*, Forum Minireview - Pharmacology and Physiology of Perivascular Nerves Regulating Vascular Function: "Role of perivascular sympathetic nerves and regional differences in the features of sympathetic innervation of the vascular system," *Jpn. J. Pharmacol.* 88(1):9-13 (2002).

DB. Velasco and Luchsinger, "Dopamine: pharmacologic and therapeutic aspects," *Am. J. Ther.* 5(1):37-43 (1998).

DC. Weimerskirch and Ernst, "Newer dopamine agonists in the treatment of restless legs syndrome," *Ann. Pharmacother.* 35:627-630 (May 2001).

DD. Winkelman *et al.*, "Restless legs syndrome in end-stage renal disease," *Am J. Kidney Dis.* 28(3):372-378 (Sept. 1996).

DE. Wolfe *et al.*, "The American College of Rheumatology 1990 - Criteria for the classification of the fibromyalgia, Report of the Multicenter Criteria Committee," *Arthritis and Rheumatism* 33(2):160-72 (Feb. 1990).

DF. Yan and Zhang, "Analysis of heart rate variability and its application," *Space Med. Med. Eng.* 10(5):318-22 (Oct. 1997).

DG. Zhang *et al.*, "Change in heart rate dynamics after aerobic training detected by approximate entropy and its association with orthostasis," *J. Gravit. Physiol.* 4(2):P-47 - P-48 (Jul. 1997).

DH. The Merck Index (Twelfth Edition), p. 301, No. 1889, Carisoprodol (1996).

DI. The Merck Index (Twelfth Edition), p. 404, No. 2449, Clonazepam (1996).

DJ. The Merck Index (Twelfth Edition), p. 733, No. 4343, Gabapentin (1996).

DK. The Merck Index (Twelfth Edition), p. 953, No. 5609, Lorazepam (1996).

DL. The Merck Index (Twelfth Edition), p. 991, No. 5857, Melatonin (1996).

DM. The Merck Index (Twelfth Edition), p. 1232, No. 7304, Pergolide (1996).

DN. The Merck Index (Twelfth Edition), p. 1321, No. 7885, Pramipexole (1996).

DO. The Merck Index (Twelfth Edition), p. 1421, No. 8416, Ropinirole (1996).

DP. The Merck Index (Twelfth Edition), p. 1618, No. 9624, Tizanidine (1996).

DQ. The Merck Index (Twelfth Edition), p. 1634, No. 9712, Trazodone (1996).

DR. Enbrel (etanercept), issued 01/2001 - Internet website: Immunex.

DS. Ambien (Zolpidem Tartrate) - "What time is it? It's time to say "Good Night" - Internet website: <http://www.ambien.com> (printed Mar. 5, 2001).

DT. Heart rate and blood pressure variability - Internet website:
<http://www.nymc.edu> (printed Feb. 26, 2002).

DU. Remicade - Drug Database - Internet website: <http://pharminfo.com> (printed Feb. 24, 2001).

DV. Sonata Zalepln capsules, Clinical overview - Internet website:
<http://www.sonatasleep.com> (printed Mar. 5, 2001).

DW. Searle Ambien (zolpidem tartrate) - Internet website:
<http://www.searlehealthnet.com> (printed Mar. 5, 2001).

DX. Healthcare Professionals, Introduction - "Eat Less - The point of change program encourages your patients to do more" - Internet website: <http://www.4meridia.com> (printed Mar. 5, 2001).

DY. Healthcare Professionals, Mechanism of Action - "Lose weight by eating less" - Internet website: <http://www.4meridia.com> (printed Mar. 5, 2001).

It is respectfully requested that the cited information be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.


Applicants believe that their invention as claimed is patentable over the above references taken alone or in any combination. However, Applicants reserve the right to demonstrate that their claimed invention was made prior to any one or more of the above-identified references. No inference should be drawn as to the pertinence of the references based on the order in which they are presented.

Applicants respectfully request that the Examiner review the foregoing references to make his own determination of the patentability of the present invention and that the references be made of record in the file of this application.

Applicant believes that no fee is required for submission of this statement, since it is being submitted prior to the first Office Action. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

Dated: 8/9/02

By: 
Mark G. Sandbaken, Ph.D.
Reg. No. 39,354

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, CA 94111
(206) 467-9600



RECEIVED
AUG 14 2002
TECH CENTER 1600/2900

FORM 1 (Modified)

Attorney Docket No.: 020862-000110US

Application No.: 10/091,744

LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE
STATEMENT (Use several sheets if necessary)

Applicant: ANDREW HOLMAN

Filing Date: March 5, 2002

Group: 1614

Reference Designation

U.S. PATENT DOCUMENTS

Page 1 of 1

Examiner Initial		Document No.	Date	Name	Class	Sub-class	Filing Date (If Appropriate)
	AA	4,452,808	6/5/84	Gallagher, Jr.			
	AB	4,843,086	6/27/89	Griss deceased <i>et al.</i>			
	AC	4,886,812	12/12/89	Griss deceased <i>et al.</i>			
	AD	5,112,842	5/12/92	Zierenberg, <i>et al.</i>			
	AE	5,650,420	7/22/97	Hall, <i>et al.</i>			
	AF	5,658,955	8/19/97	Hitzig			
	AG	5,694,950	12/9/97	McMichael			
	AH	5,696,128	12/9/97	Cincotta, <i>et al.</i>			
	AI	5,786,344	7/28/98	Ratain <i>et al.</i>			
	AJ	5,842,997	12/1/98	Verrier <i>et al.</i>			
	AK	5,843,943	12/1/98	Carson <i>et al.</i>			
	AL	5,872,127	2/16/99	Cincotta <i>et al.</i>			
	AM	5,872,133	2/16/99	Cincotta <i>et al.</i>			
	AN	5,905,083	5/18/99	Cincotta <i>et al.</i>			
	AO	5,921,940	7/13/99	Verrier <i>et al.</i>			
	AP	5,932,252	8/3/99	Morris Jr. <i>et al.</i>			
	AQ	5,952,389	9/14/99	Fogel			
	AR	6,001,861	12/14/99	Oertel <i>et al.</i>			
	AS	6,057,373	5/2/00	Fogel			
	AT	6,156,777	12/5/00	Hall <i>et al.</i>			
	AU	6,191,153	2/20/01	Hammer <i>et al.</i>			
	AV	6,194,445	2/27/01	Oertel <i>et al.</i>			
	AW	6,204,245	3/20/01	Siegel <i>et al.</i>			
	AX	6,255,329	7/3/01	Maj			
	AY	6,258,827	7/10/01	Chenard <i>et al.</i>			
	AZ	6,277,875	8/21/01	Holman			
	BA	6,294,583	9/25/01	Fogel			
	BB	6,300,365	10/9/01	Holman			

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)




RECEIVED

AUG 14 2002

TECH CENTER 1600/2900

FORM PTO/J-100 (Modified)		Attorney Docket No.: 020862-000110US	Application No. 00/000000
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: ANDREW HOLMAN	
		Filing Date: March 5, 2002	Group: 1614
BC	Aksoyek <i>et al.</i> , "Assesment of autonomic nervous system function in patients with Behcet's disease by spectral analysis of heart rate variability," <i>J. Auton. Nerv. Syst.</i> 77(2-3):190-4 (Sept. 24, 1999).		
BD	Alvarez-Nemegyei <i>et al.</i> , "Bromocriptine in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled study," <i>Lupus</i> 7(6):414-9 (1998).		
BE	Bathon, "Rheumatoid Arthritis-treatment," Abstract from the Highlights of the 1998 American College of Rheumatology National Scientific Meetings.		
BF	Breedveld, "New tumor necrosis factor-alpha biologic therapies for rheumatoid arthritis," <i>Eur. Cytokine Netw.</i> 9:233-38 (1998).		
BG	British Society for Rheumatology, The Programme from the XIXth Annual General Meeting, Brighton, UK (April 23-26, 2002).		
BH	Chokroverty and Jankovic, "Restless legs syndrome: A disease in search of identity," <i>Neurology</i> 52(5):907-10 (Mar. 23, 1999).		
BI	Damase-Michel <i>et al.</i> , "Effects of dopaminergic drugs on the sympathoadrenal system," <i>Hypertens Res.</i> 18(1):1:S119-24 (1995).		
BJ	Drewes, "Pain and sleep disturbances with special reference to fibromyalgia and rheumatoid arthritis," <i>Rheumatology (Oxford)</i> 38(11):1035-1038 (Nov. 1999).		
BK	Eijsbouts <i>et al.</i> , "Treatment of rheumatoid arthritis with the dopamine agonist quinagolide," <i>J. Rheumatol.</i> 26(10):2284-5 (Oct. 1999).		
BL	Elenkov <i>et al.</i> , "The Sympathetic Nerve - An Integrative Interface between Two Supersystems: The Brain and the Immune System," <i>Pharmacological Review</i> 52(4):595-638 (2000).		
BM	Gao <i>et al.</i> , "Effects of dopaminergic agents on carrageenan hyperalgesia in rats," <i>Eur. J. Pharmacol.</i> 406(1): 53-8 (2000).		
BN	Hanna <i>et al.</i> , "Switching from pergolide to pramipexole in patients with Parkinson's disease," <i>J. Neural. Transm.</i> 108:63-70 (2001).		
BO	Hennig, "Restless Leg Syndrome: Diagnosis and Treatment," <i>Hospital Medicine</i> , pp. 54-75 (Nov. 1997).		
BP	Holman, "Pramipexole for Fibromyalgia: Initial Observations and Rationale," Abstract: FAME meeting, Chicago, IL (Jun. 22-23, 2001).		
BQ	Holman, "The Relationship of Sleep and Autonomic Function on Autoimmune Disease," Abstract: FAME meeting, Chicago, IL (Jun. 22-23, 2001).		
BR	Holman, "Safety and Efficacy of Sleep of the Dopamine Agonist, Pramipexole, on Pain Score for Refractory Fibromyalgia," Arthritis and Rheumatism, Abstract for: 2000 Annual Scientific Meeting 43:9 1599 (2000).		
BS	Honda <i>et al.</i> , "Dopamine D ₃ agonists into the substantia nigra aggravates cataplexy but do not modify sleep," <i>NeuroReport</i> 10(14): 3111-8 (Sept. 1999).		
BT	Huynh <i>et al.</i> , "The Effects of Pramipexole in a Rodent Model of Early Parkinson's Disease," Online Abstract, Short Term Training Program, Department of Neurology, School of Medicine, UCLA, Los Angeles, CA (Summer 2001).		
BU	Lagos <i>et al.</i> , "Effects of the D ₃ preferring dopamine agonist pramipexole on sleep and waking, locomotor activity and striatal dopamine release in rats," <i>Eur. Neuropsychopharmacol.</i> 8(2):113-20 (May 1998).		
BV	Lam, "Clinical pharmacology of dopamine agonists," <i>Pharmacotherapy</i> 20(1 Pt. 2): 17S-25S (2000).		
BW	Leanos Miranda <i>et al.</i> , "Prolactin as an immunomodulator," <i>Rev. Alerg. Mex.</i> 44(5):116-23 (Sept-Oct., 1997).		
BX	Lechin <i>et al.</i> , "Plasma neurotransmitters and cortisol in chronic illness: role of stress," <i>J. Med.</i> 25(3-4): 181-92 (1994).		
BY	Lieberman, "Management of Patients With Newly Diagnosed PD," Published in <i>Young Parkinson's Handbook</i> , Chapter 3: The Medical Management of PD, http://spauldingrehab.mgh.harvard.edu (printed Nov. 19, 2001).		



RECEIVED

AUG 1 4 2002

FORM PTO-1449 (Modified)		Attorney Docket No.: 020862-000110US	Application No. 09/1600/2900
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: ANDREW HOLMAN	
		Filing Date: March 5, 2002	Group: 1614
BZ	Lin <i>et al.</i> , "Effect of pramipexole in treatment of resistant restless legs syndrome," <i>Mayo Clin. Proc.</i> 73(6):497-500 (Jun. 1998).		
CA	Lorenc-Koci and Wolfarth, "Efficacy of pramipexole, a new dopamine receptor agonist, to relieve the Parkinsonian-like muscle rigidity in rats," <i>Eur. J. Pharmacol.</i> 385(1):39-46 (1999).		
CB	Luchsinger <i>et al.</i> , "Comparative effects of dopaminergic agonists on cardiovascular, renal, and renin-angiotensin systems in hypertensive patients," <i>J. Clin. Pharmacol.</i> 32(1):55-60 (1992).		
CC	Mader, "Bromocriptine for refractory rheumatoid arthritis," <i>Harefuah</i> 133(11):527-9, 591 (Dec. 1, 1997).		
CD	Maj <i>et al.</i> , "Antidepressant effects of pramipexole, a novel dopamine receptor agonist," <i>J. Neural. Transm.</i> 104: 4-5, 525-33 (1997).		
CE	Maj <i>et al.</i> , "The effect of repeated treatment with pramipexole on the central dopamine D ₃ system," <i>J. Neural. Transm.</i> 107(12): 1369-79 (2000).		
CF	Mannelli <i>et al.</i> , "In Vivo Evidence That Endogenous Dopamine Modulates Sympathetic Activity in Man," <i>Hypertension</i> 34:398-402 (1999).		
CG	Mannelli <i>et al.</i> , "Dopamine and sympathoadrenal activity in man," <i>Clin. Exp. Hypertens.</i> 19(1-2):163-79 (1997).		
CH	Martinez-Lavin <i>et al.</i> , "Circadian studies of autonomic nervous balance in patients with fibromyalgia," <i>Arthritis & Rheumatism</i> 41:1966-71 (Nov. 1998).		
CI	Mehta <i>et al.</i> , "Heart rate variability in healthy newborn infants," <i>Am. J. Cardiol.</i> 89(1):50-3 (Jan. 1, 2002).		
CJ	Mohler <i>et al.</i> , "Pramipexole in the treatment of advanced Parkinson's disease," <i>Eur. J. Neurology Suppl.</i> (Suppl. 1):21-25 (2000).		
CK	Mohler <i>et al.</i> , "Soluble Tumor Necrosis Factor (TNF) Receptors Are Effective Therapeutic Agents in Lethal Endotoxemia and Function Simultaneously as Both TNF Carriers and TNF Antagonists," <i>J. Immunol.</i> 151:1548-1561 (Aug. 1, 1993).		
CL	Monti and Monti, "Role of dorsal raphe nucleus serotonin 5-HT _{1A} receptor in the regulation of REM sleep," <i>Life Sci.</i> 66(21):1999-2012 (2000).		
CM	Montplaisir <i>et al.</i> , "Restless legs syndrome improved by pramipexole: a double-blind randomized trial," <i>Neurology</i> 52(5):938-43 (1999).		
CN	Montplaisir <i>et al.</i> , "Pramipexole in the treatment of restless legs syndrome: a follow-up study," <i>Eur. J. Neurol.</i> 7 Suppl. 1:27-31 (May 2000).		
CO	Orr <i>et al.</i> , "Autonomic regulation of cardiac function during sleep in patients with irritable bowel syndrome," <i>Am. J. Gastroenterol.</i> 95(10): 2865-71 (2000).		
CP	Penzel <i>et al.</i> , "Heart rate variability during sleep stages in normals and in patients with sleep apnea," <i>Stud. Health Technol. Inform.</i> 77:1256-60 (2000).		
CQ	Prescott (ed.), "Lipid Vesicles as Carriers for Introducing Biologically Active Materials into Cells," <i>Methods in Cell Biology</i> , Volume XIV, Ch. 4, Academic Press, New York, N.Y. (1976).		
CR	Quinn <i>et al.</i> , "Painful Parkinson's Disease," <i>Lancet</i> 1(8494):1366-9 (Jun. 14, 1986).		
CS	Renzetti and Gater, "Ro 45-2081, a TNF receptor fusion protein, prevents inflammatory responses in the airways," <i>Inflamm. Res.</i> 46(2):S143-S144 (1997).		
CT	Schilling <i>et al.</i> , "Neuroendocrine and side effect profile of pramipexole, a new dopamine receptor agonist, in humans," <i>Clin. Pharmacol. Ther.</i> 51(5):541-8 (May 1992).		
CU	Sears, "The evolution of β_2 -agonists," <i>Respir. Med.</i> 95(B): S2-6 (Aug. 2001).		
CV	Silber, "Concise review for Primary-Care Physicians: Restless legs syndrome," <i>Mayo Clin. Proc.</i> 72(3):261-4 (Mar. 1997).		



RECEIVED

AUG 1 4 2002

TECH CENTER 1600/2900

FORM PTO-1449 (Modified)		Attorney Docket No.: 020862-000110US	Application No.: 10/091,744
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: ANDREW HOLMAN	
		Filing Date: March 5, 2002	Group: 1614
CW	Sinoway, "Direct Assessment of Sympathetic Neural Activity in Patients with Heart Failure During Exercise," Abstract from Research Workshop entitled "Effect of Acupuncture on Cardiovascular Disease, Its Mechanism and Clinical Application", University of California at Irvine (Oct. 14-15, 2000).		
CX	Sjolin and Trykker, " Unsuccessful treatment of severe pain from bone metastasis with Sinemet 25/100," <i>N. Engl. J. Med.</i> 312(10):650-1 (Mar. 7, 1985).		
CY	Sun <i>et al.</i> , "Iron and the restless legs syndrome," <i>Sleep</i> 21(4):371-7 (1998).		
CZ	Trenkwalder <i>et al.</i> , "Periodic limb movements and restless legs syndrome," <i>Neurol. Clin.</i> 14(3):629-50 (Aug. 1996).		
DA	Tsuru <i>et al.</i> , Forum Minireview - Pharmacology and Physiology of Perivascular Nerves Regulating Vascular Function: "Role of perivascular sympathetic nerves and regional differences in the features of sympathetic innervation of the vascular system," <i>Jpn. J. Pharmacol.</i> 88(1):9-13 (2002).		
DB	Velasco and Luchsinger, "Dopamine: pharmacologic and therapeutic aspects," <i>Am. J. Ther.</i> 5(1):37-43 (1998).		
DC	Weimerskirch and Ernst, "Newer dopamine agonists in the treatment of restless legs syndrome," <i>Ann. Pharmacother.</i> 35:627-30 (May 2001).		
DD	Winkelman <i>et al.</i> , "Restless legs syndrome in end-stage renal disease," <i>Am J. Kidney Dis.</i> 28(3):372-378 (Sept. 1996).		
DE	Wolfe <i>et al.</i> , " The American College of Rheumatology 1990 - Criteria for the classification of the fibromyalgia, Report of the Multicenter Criteria Committee," <i>Arthritis and Rheumatism</i> 33(2):160-72 (Feb. 1990).		
DF	Yan and Zhang, " Analysis of heart rate variability and its application," <i>Space Med. Med. Eng.</i> 10(5):318-22 (Oct. 1997).		
DG	Zhang <i>et al.</i> , "Change in heart rate dynamics after aerobic training detected by approximate entropy and its association with orthostasis," <i>J. Gravit. Physiol.</i> 4(2):P-47 - P-48 (Jul. 1997).		
DH	The Merck Index (Twelfth Edition), p. 301, No. 1889, Carisoprodol (1996).		
DI	The Merck Index (Twelfth Edition), p. 404, No. 2449, Clonazepam (1996).		
DJ	The Merck Index (Twelfth Edition), p. 733, No. 4343, Gabapentin (1996).		
DK	The Merck Index (Twelfth Edition), p. 953, No. 5609, Lorazepam (1996).		
DL	The Merck Index (Twelfth Edition), p. 991, No. 5857, Melatonin (1996).		
DM	The Merck Index (Twelfth Edition), p. 1232, No. 7304, Pergolide (1996).		
DN	The Merck Index (Twelfth Edition), p. 1321, No. 7885, Pramipexole (1996).		
DO	The Merck Index (Twelfth Edition), p. 1421, No. 8416, Ropinirole (1996).		
DP	The Merck Index (Twelfth Edition), p. 1618, No. 9624, Tizanidine (1996).		
DQ	The Merck Index (Twelfth Edition), p. 1634, No. 9712, Trazodone (1996).		
DR	Enbrel (etanercept), issued 01/2001 - Internet website: Immunex.		
DS	Ambien (Zolpidem Tartrate) - "What time is it? It's time to say "Good Night" - Internet website: http://www.ambien.com (printed Mar. 5, 2001).		
DT	Heart rate and blood pressure variability - Internet website: http://www.nymc.edu (printed Feb. 26, 2002).		
DU	Remicade - Drug Database - Internet website: http://pharminfo.com (printed Feb. 24, 2001).		
DV	Sonata Zalepln capsules, Clinical overview - Internet website: http://www.sonatasleep.com (printed Mar. 5, 2001).		
DW	Searle Ambien (zolpidem tartrate) - Internet website: http://www.searlehealthnet.com (printed Mar. 5, 2001).		
DX	Healthcare Professionals, Introduction - "Eat Less - The point of change program encourages your patients to do more" - Internet website: http://www.4meridia.com (printed Mar. 5, 2001).		

RECEIVED

AUG 14 2002

TECH CENTER 1600/2900

FOR PTO-1449 (modified)		Attorney Docket No.: 020862-000110US	Application No.: 10/091,744
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: ANDREW HOLMAN	
		Filing Date: March 5, 2002	Group: 1614
DY	Healthcare Professionals, Mechanism of Action- "Lose weight by eating less"- Internet website: http://www.4meridia.com (printed Mar. 5, 2001).		
EXAMINER		DATE CONSIDERED	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.